Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma
Source: SeekingAlpha
2025-04-01 12:18:53 ET
More on Eton Pharmaceuticals
- Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript
- Eton Pharmaceuticals receives new U.S. patent for ET-600
- FDA extends target action date for Eton's ET-400
- Seeking Alpha’s Quant Rating on Eton Pharmaceuticals
- Historical earnings data for Eton Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
March 09, 2026 02:00:00 am
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
